RSS-Feed abonnieren
DOI: 10.1055/s-0039-1684026
Successful Management of Pulmonary Arterial Hypertension by Monitoring N-Terminal Pro-B-Type Natriuretic Peptide Serum Levels in a Preterm Infant with Chronic Lung Disease: A Case Report
Funding Equipment provided by the Hamamatsu University School of Medicine was used. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Each author listed on the manuscript has seen and approved the submission of this version of the manuscript and takes full responsibility for the manuscript. If the article is accepted for publication, the disclosure statement may be published. This study has no sponsor. This is a case report. The decision to submit the manuscript for publication was made by Satoru Iwashima. The author who wrote the first draft of the manuscript is Satoru Iwashima. There was no honorarium, grant, or other form of payment made to produce this manuscript.Publikationsverlauf
05. November 2018
24. Februar 2019
Publikationsdatum:
09. April 2019 (online)
Abstract
We measured the serial changes in N-terminal probrain natriuretic peptide (NT-proBNP) levels in a 6-month-old male infant with chronic lung disease (CLD) complicated by pulmonary arterial hypertension (PAH). The patient was born at the 24th week of gestation weighing 695 g. At 1 month after birth, an echocardiogram confirmed the diagnosis of CLD with PAH. He was treated with inhaled nitric oxide (iNO) and oral sildenafil and discharged from the hospital. At 190 days of age, the patient was readmitted to our department because of a viral upper respiratory infection. At 195 days of age, his respiratory condition worsened with pulmonary edema and his NT-proBNP level was determined to be 10,117 pg/mL. The patient was immediately administered iNO, and his respiratory condition improved, and NT-proBNP levels decreased. However, he experienced repeated severe cyanosis attacks. Before the attacks, his NT-proBNP level was > 1,000 pg/mL. Therefore, we continuously administered iNO until his NT-proBNP level decreased to < 1,000 pg/mL. We safely discontinued iNO administration at 473 days of age. In conclusion, serial change in NT-proBNP is a surrogate marker with prognostic value in patients with PAH associated with CLD.
-
References
- 1 Khemani E, McElhinney DB, Rhein L. , et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007; 120 (06) 1260-1269
- 2 Slaughter JL, Pakrashi T, Jones DE, South AP, Shah TA. Echocardiographic detection of pulmonary hypertension in extremely low birth weight infants with bronchopulmonary dysplasia requiring prolonged positive pressure ventilation. J Perinatol 2011; 31 (10) 635-640
- 3 Check J, Gotteiner N, Liu X. , et al. Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia. J Perinatol 2013; 33 (07) 553-557
- 4 Bhat R, Salas AA, Foster C, Carlo WA, Ambalavanan N. Prospective analysis of pulmonary hypertension in extremely low birth weight infants. Pediatrics 2012; 129 (03) e682-e689
- 5 Kalra VK, Aggarwal S, Arora P, Natarajan G. B-type natriuretic peptide levels in preterm neonates with bronchopulmonary dysplasia: a marker of severity?. Pediatr Pulmonol 2014; 49 (11) 1106-1111
- 6 Joseph L, Nir A, Hammerman C, Goldberg S, Ben Shalom E, Picard E. N-terminal pro-B-type natriuretic peptide as a marker of bronchopulmonary dysplasia in premature infants. Am J Perinatol 2010; 27 (05) 381-386
- 7 Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004; 6 (03) 365-368
- 8 Sugimoto M, Manabe H, Nakau K. , et al. The role of N-terminal pro-B-type natriuretic peptide in the diagnosis of congestive heart failure in children. - Correlation with the heart failure score and comparison with B-type natriuretic peptide -. Circ J 2010; 74 (05) 998-1005
- 9 Pemberton CJ, Johnson ML, Yandle TG, Espiner EA. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000; 36 (03) 355-359
- 10 Leuchte HH, Baumgartner RA, Nounou ME. , et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006; 173 (07) 744-750
- 11 Fijalkowska A, Kurzyna M, Torbicki A. , et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129 (05) 1313-1321
- 12 Cuna A, Kandasamy J, Sims B. B-type natriuretic peptide and mortality in extremely low birth weight infants with pulmonary hypertension: a retrospective cohort analysis. BMC Pediatr 2014; 14: 68
- 13 Abman SH, Hansmann G, Archer SL. , et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; and the American Thoracic Society. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation 2015; 132 (21) 2037-2099
- 14 Krishnan U, Feinstein JA, Adatia I. , et al; Pediatric Pulmonary Hypertension Network (PPHNet). Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. J Pediatr 2017; 188: 24-34.e1
- 15 Shaffer TH, Bhutani VK, Wolfson MR, Penn RB, Tran NN. In vivo mechanical properties of the developing airway. Pediatr Res 1989; 25 (02) 143-146